It is essential to potentiate the human respiratory system’s antiviral immune defenses to reduce severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral shedding in the upper respiratory tract (URT) and control the viral transmission. A prophylactic intranasal administration of the TLR2/6 agonist INNA-051 exhibits viral reduction – this offers a promising approach for possible prevention and management of SARS-CoV-2 infection, particularly useful to individuals at elevated risk of community transmission.
The respiratory virus, SARS-CoV-2, causing the current COVID-19 disease pandemic, initially infects the upper respiratory tract (URT). Infected people may be symptomatic, pre- or asymptomatic, spreading the virus nonetheless. Asymptomatic individuals shed the virus and transmit the disease longer than those with symptoms. It is essential to restrict the initial replication of the virus in URT to prevent the progression of the disease. In a recent bioRxiv* preprint paper, Professor Miles W. Carroll et al. study an agonist for